Dr. Dennis Yamashita is a highly experienced and accomplished drug hunter and medicinal chemist with extensive leadership experience at GSK and in biotech. He is co-inventor of five clinical candidates including oliceridine (OLINVO), Trevena’s Mu opioid G-protein biased ligand, that has received FDA breakthrough status and has completed Phase 3 clinical trials (NDA filed Nov 2017) for post-operative pain.
Prior to joining Axial Biotherapeutics, Dr. Yamashita held various leadership roles at GSK, ORIC, and Trevena. At GSK, he was Executive Director in Discovery Partnerships with Academia and was based in Cambridge, MA, and was also Director of Medicinal Chemistry in Microbial, Musculoskeletal, and Proliferative Diseases Center of Excellence Drug Discovery in Philadelphia, PA. Most recently, he was VP Drug Discovery of ORIC (Overcoming Resistance in Cancer) and was formerly VP Chemistry at Trevena.
Dr. Yamashita holds a Bachelor of Science in Chemistry from MIT and a Ph.D. in Organic Chemistry from Yale University. His Ph.D. thesis was conducted in the labs of Prof. Samuel J. Danishefsky on the synthesis of the bicyclic enediyne natural product, calicheamicinone.